Carmen Martínez, Segismundo Galván, Elena Garcia‐Martin, María I. Ramos, Yolanda Gutiérrez‐Martín, José A.G. Agúndez – 25 January 2010 – Association between genetic variations in alcohol‐related enzymes and impaired ethanol biodisposition has not been unambiguously proven, and the effect of many newly described polymorphisms remains to be explored. The aims of this study are to elucidate the influence of genetic factors in alcohol biodisposition and effects.

Inge Mannaerts, Nele R. Nuytten, Vera Rogiers, Karin Vanderkerken, Leo A. van Grunsven, Albert Geerts – 25 January 2010 – Hepatic stellate cell (HSC) activation is a pivotal step in the pathogenesis of liver fibrosis. The clarification of this transdifferentiation process is therefore important for the development of effective therapies for fibrosis. We analyzed the effect of a histone deacetylase inhibitor, valproic acid (VPA), on mouse HSC transdifferentiation in vitro and in vivo.

Ting‐Tsung Chang, Ching‐Lung Lai, Seung Kew Yoon, Samuel S. Lee, Henrique Sergio M. Coelho, Flair Jose Carrilho, Fred Poordad, Waldemar Halota, Yves Horsmans, Naoky Tsai, Hui Zhang, Daniel J. Tenney, Ricardo Tamez, Uchenna Iloeje – 25 January 2010 – Sustained virologic suppression is a primary goal of therapy for chronic hepatitis B (CHB). In study entecavir (ETV)‐022, 48 weeks of entecavir 0.5 mg was superior to lamivudine for virologic suppression for hepatitis B e antigen (HBeAg)‐positive CHB. A total of 183 entecavir‐treated patients from ETV‐022 subsequently enrolled in study ETV‐901.

Karolina A. Rygiel, Helen Robertson, Joseph D. P. Willet, John G. Brain, Alastair D. Burt, David E. J. Jones, John A. Kirby – 25 January 2010 – Loss of bile duct epithelium is characteristic of early chronic rejection following liver transplantation. Recent studies have suggested that intrahepatic biliary epithelial cells can transform into myofibroblasts. This study examines the induction and molecular regulation of this transition during allograft rejection.

Stephen A. Harrison – 25 January 2010

Michael G. Lenos, Sofia‐Maria Tsaniklidou – 25 January 2010

David Mutimer – 21 January 2010

Adriana Zeevi, John G. Lunz – 21 January 2010

Costi D. Sifri, Hsin‐Yun Sun, Thomas V. Cacciarelli, Brian Wispelwey, Timothy L. Pruett, Nina Singh – 21 January 2010 – The posttransplant outcomes and optimal management of patients with end‐stage liver disease who develop cryptococcosis prior to transplantation have not been defined. We discuss these issues in the context of successful liver transplantation and pretransplant cryptococcal disease.

Jae Myeong Lee, Gi‐Young Ko, Kyu‐Bo Sung, Dong Il Gwon, Hyun‐Ki Yoon, Sung‐Gyu Lee – 21 January 2010 – The aims of this study were to evaluate both the efficacy of stent placement for treating inferior vena cava (IVC) stenosis and the patency of hepatic veins (HVs) following IVC stent placement. Fourteen hepatic transplant recipients underwent stent placement to treat IVC stenosis. The median interval between transplantation and stent placement was 32 days. Stents varied from 20‐36 mm in diameter and were 60‐120 mm long.